What is new in the treatment of steroid-induced osteoporosis?
被引:6
|
作者:
Liu, Rosemarie H.
论文数: 0引用数: 0
h-index: 0
机构:
Yale New Haven Med Ctr, Dept Internal Med, New Haven, CT 06504 USAYale New Haven Med Ctr, Dept Internal Med, New Haven, CT 06504 USA
Liu, Rosemarie H.
[1
]
Werth, Victoria P.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
VA Hosp, Philadelphia, PA USAYale New Haven Med Ctr, Dept Internal Med, New Haven, CT 06504 USA
Werth, Victoria P.
[2
,3
]
机构:
[1] Yale New Haven Med Ctr, Dept Internal Med, New Haven, CT 06504 USA
[2] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
Glucocorticoid-induced osteoporosis (GIOP) is a serious complication resulting from long-term steroid treatment. In addition to several nonpharmacologic therapies recommended by the American College of Rheumatology, various pharmacologic therapies, such as calcium, vitamin D, hormone-replacement therapy, calcitonin, and bisphosphonates, can be used to prevent and/or treat GIOP. Bisphosphonates, which are potent inhibitors of bone resorption, are considered the most effective and first-line agents for increasing bone mineral density and decreasing the risk of fracture. Human parathyroid hormone has emerged as a promising agent for the treatment of severe GIOP when used alone or in combination with a bisphosphonate.
机构:
Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R ChinaUniv Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
Lambrinoudaki, I
Kung, AWC
论文数: 0引用数: 0
h-index: 0
机构:
Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R ChinaUniv Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
机构:
Univ Bristol, Bristol Royal Infirm, Rheumatol Unit, Bristol BS2 8HW, Avon, EnglandUniv Bristol, Bristol Royal Infirm, Rheumatol Unit, Bristol BS2 8HW, Avon, England